Trial Profile
A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Guadecitabine (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Gallbladder cancer; Liver cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Jan 2024 Planned End Date changed from 2 Mar 2024 to 2 Jun 2024.
- 05 Apr 2023 Planned End Date changed from 2 Mar 2023 to 2 Mar 2024.
- 05 Aug 2022 Planned End Date changed from 2 Mar 2022 to 2 Mar 2023.